Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients

Journal of the American Society of Nephrology

Volumn 10, Issue 11, 1999, Pages 2392-2395

  Macdougall, Iain C ^a   Gray, Stephen J ^b   Elston, Orlaith ^a   Breen, Cormac ^a   Jenkins, Barbara ^b   Browne, Jeff ^c   Egrie, Joan ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b AMGEN LTD   (United Kingdom)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032737391     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v10112392     Document Type: Article

References (13)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet I: 1175-1178, 1986
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73-78, 1987
3. Egrie JC, Dwyer E, Lykos M, Hitz A, Browne JK: Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity compared to recombinant human erythropoietin (rHuEPO) [Abstract]. Blood 90: 56a, 1997
4. Egrie JC, Grant JR, Gillies DK, Aoki KH, Strickland TW: The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 10: 263, 1993
5. Hills M, Armitage P: The two-period cross-over clinical trial. Br J Clin Pharmacol 8: 7-20, 1979
6. Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD: Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet I: 425-427, 1989
7. Boelaert JR, Schurgers ML, Matthys EG, Belpaire FM, Daneels RF, De Cre MJ, Bogaert MG: Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 9: 95-98, 1989
8. Macdougall IC, Roberts DE, Coles GA, Williams JD: Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinetics 20: 99-113, 1991
9. Halstenon CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT: Comparative pharmacokinetics of epoetin alfa and beta. Clin Pharmacol Ther 50: 702-712, 1991
10. Faulds D, Sorkin EM: Epoetin (recombinant human erythropoietin): A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 38: 863-899, 1989
11. Flaharty KK: Clinical pharmacology, of recombinant human erythropoietin (r-HuEPO). Pharmacotherapy 10: 9S-14S, 1990
12. Varki A: Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3: 97-130, 1993
13. Korbett SM: Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int 43: S111-S119, 1993